We are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the immune system’s strength by activating and recruiting myeloid cells to […]

Vor Biopharma’s mission is to develop transformative treatments for patients suffering from hematological malignancies. We are a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure […]

We are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. We aim to inhibit the inflammatory responses by changing the metabolic processes in target cells. Through our […]

We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as […]

We intend to focus on industries that complement our management team’s background and to capitalize on the ability of our management team and the broader Noble Rock Advisors platform to identify, acquire and operate a business in the software and tech-enabled services sectors. We will seek to acquire one or more businesses with an aggregate enterprise […]

We were created to take advantage of transformative macro and micro trends occurring domestically and internationally, driven by the impact of technology on how work is executed, facilitated and enhanced.  Our executive co-chairman, Doug Atkin, is a co-founder and managing partner at Communitas Capital, a venture fund he launched in 2018 with Tom Glocer (former CEO […]

We currently intend to concentrate our efforts in identifying businesses in the industrial technology, advanced materials or specialty chemicals industries (collectively, “Advanced Industrials”). A common theme across these sectors is the application of technology to make industrial processes more profitable, faster, more sustainable, less capital-intensive and less complex. Specifically, we intend to identify businesses that […]

We intend to capitalize on our management team’s ability to identify, acquire and manage an undervalued, growth-oriented business in the healthcare services industry that can benefit from our differentiated and proprietary deal flow, leading brand name and global network. Our search for target healthcare businesses will include clinics and alternative healthcare facilities, senior care facilities […]

James McCann, the chairman of 1-800-Flowers.com (NASDAQ: FLWS), is our chairman and CEO. We intend to focus our search primarily within the consumer-facing e-commerce sector. We will seek to acquire companies with a predictable and stable business with an enterprise value above $750 million. We believe COVID-19 has proven to be a catalyst for growth in our potential target universe, […]

We intend to capitalize on our management team’s experience and domain knowledge across specific sectors, including information technology (“IT”), healthcare, business services, and financial services. We may also consider companies that are geared towards addressing evolving environmental, social and governance (“ESG”) related issues. (We are a new blank-check company organized under the laws of Delaware.) […]